Source: Simply Better Brands.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Simply Better Brands’ (SBBC) PureKana brand has been recognized by the Brightfield Group as one of the fastest growing brands in the emerging CBD category
  • Brightfield Group is a leading research firm for emerging categories including CBD, cannabis, and wellness
  • PureKana is adding 15,000 new customers per month driving year-to-date growth of 366 per cent
  • Simply Better Brands (SBBC) is an omni-channel platform with diverse assets in the emerging plant-based and holistic wellness consumer product categories
  • Simply Better Brands Corp. (SBBC) opened trading at C$0.74

Simply Better Brands’ (SBBC) PureKana brand has been recognized by the Brightfield Group as one of the fastest growing brands in the CBD category.

Brightfield Group is a leading research firm for emerging categories including CBD, cannabis, and wellness.

Simply Better Brands CEO, Kathy Casey, commented on the news.

“In the roughly $5B CBD category of over 3,000 brands, our Q1 2022 performance places us with the Top 10 brand performers. Consumers are rewarding us for consumer-centric active ingredient wellness innovation in the need states of anxiety, pain, sleep, immunity, energy, and recreation. Our growth priority remains to relentlessly acquire customers by driving customer, category, channel and geographic expansion.”

The company’s CBD subsidiary brand, PureKana, has added approximately 15,000 new customers per month, driving year-to-date growth of 366 per cent.

Simply Better Brands (SBBC) is an omni-channel platform with diverse assets in the emerging plant-based and holistic wellness consumer product categories.

Simply Better Brands Corp. (SBBC) opened trading at C$0.74.

More From The Market Herald
Emerald Health Therapeutics Inc. - Director & Chairman, Jim Heppell.

" Emerald Health (CSE:EMH) shareholders approve merger

Emerald Health Therapeutics (EMH), has received shareholders’ approval for the proposed plan of arrangement with Skye Bioscience Inc.
Mydecine Innovations Group - CEO, Josh Bartch.

" Mydecine (NEO:MYCO) raises $244K and shifts management team

Mydecine Innovations Group (MYCO) has signed a common share subscription agreement with a third-party investor for proceeds up to $244,99.50.
PharmaDrug - CEO, Daniel Cohen

" PharmaDrug (CSE:PHRX) completes milestone to support cGMP production of PD-001

PharmaDrug (PHRX) has laid the groundwork to support cGMP production of cepharanthine-2HCL for use in the drug product production of PD-001.

" Hemostemix (TSXV:HEM) announces $1.5M non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 5 million units for gross proceeds of up to $1.5 million.